Search for a trial

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

EFFICACY OBJECTIVESThe primary efficacy objective of this study is to evaluate the efficacy of intravitreal injections of 10 mg lampalizumab administered Q4W or Q6W in CFI profile biomarker positive and CFI profile biomarker-negative patients…

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

EFFICACY OBJECTIVESThe primary efficacy objective of this study is to evaluate the efficacy of intravitreal injections of 10 mg lampalizumab administered Q4W or Q6W in CFI profile biomarker positive and CFI profile biomarker-negative patients…

A phase 2b randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista® (Anti-PDGFBB pegylated aptamer) administered in combination with Avastin® compared to Avastin® monotherapy in subjects with subfoveal neovascular age-related macular degeneration.

The objective of this trial is to evaluate the safety and efficacy of the combination of Fovista® intravitreous administration with Avastin® compared to Avastin® monotherapy.

Clinical Investigation of Visual Function After Bilateral Implantation of Two Presbyopia-Correcting Trifocal IOLs.

Primary Objective:To demonstrate noninferiority of ACRYSOF IQ PanOptix presbyopia-correcting IOL Model TFNT00 to the AT LISA tri IOL Model 839MP in mean photopic binocular uncorrected intermediate (60 cm) visual acuity at Visit 4A.Secondary…

A randomized, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks (q3W) by intravenous (iv) infusion in patients suffering from active thyroid eye disease (TED)

The primary objective is to investigate the efficacy, safety and tolerability of RV 001 (a fully human anti-IGF-1R antibody) administered q3W for 6 months, in comparison to placebo, in the treatment of patients suffering from active TED.Secondary…

Efficacy and cost-effectiveness of toric intraocular lenses in correcting astigmatism in cataract surgery: A Randomised Clinical Trial

The primary objective of this study is to compare the quality of vision following toric IOL implantation and monofocal IOL implantation. The secondary objectives are to compare uncorrected distance vision, spectacle dependence, residual refractive…

Prevalence of amblyopia, strabismus and refractive errors amongst children of the 7th grade and influence of spectacle correction of hypermetropia on reading ability

Main objectives: 1. to investigate the prevalence of vision abnormalities in 9- and 10 year old children; 2. to investigate the percentage of these vision abnormalities that were detected the VOV screening programme;3. to investigate whether these…

A double blind randomized study on the efficacy of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in children

To compare one dose of the short acting tropicamide combined with one dose of the longer acting cyclopentolate (c+t) with a double dose of the longer acting cyclopentolate (c+c). To develop a cycloplegics protocol that garantees optimal refractieve…

Effect of improved intraocular lenses on contrast sensitivity tests

The aim of this study is to measure the results of refractive surgery with aspherical intra-ocular lenses quickly and reliably.

A double blind randomized study on the effectiveness of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in dark irided hypermetropic children

To compare the effectiveness of 1) double dose of cyclopentolate and 2) one dose of cyclopentolate and one dose of tropicamide with 3 days, total 5 doses atropine.To investigate whether one dose of tropicamide combined with cyclopentolate is as…

Childhood Atropine for Myopia Progression (CHAMP): A 3-Arm Randomized,
Double-Masked, Placebo-Controlled, Phase 3 Study of Atropine Sulfate Ophthalmic Solution 0.01%
and 0.02%

Primary Objective: To evaluate the safety and efficacy of 2 concentrations of Atropine Sulfate OphthalmicSolution (0.01% and 0.02%) compared to Vehicle (placebo) for slowing the progression of myopia inchildren over a 3-year treatment period.…

A phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter study of the
safety and efficacy of OT-101 (Atropine Sulfate 0.01%) in treating the progression of myopia in
pediatric subjects

To evaluate the efficacy of OT-101 Ophthalmic Solution in treating the progression of myopia in pediatric subjects following 3 years of treatment.To evaluate the safety and tolerability of OT-101 Ophthalmic Solution in pediatric subjects with myopia…